Get started
Author

Terri Ridenour

Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial
2020 · Andrew Blauvelt, Mark G. Lebwohl, et al. · Journal of the American Academy of Dermatology · 74
Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open-label Study of Patients with Moderate-to-severe Plaque Psoriasis.
2018 · Saakshi Khattri, Orin Goldblum, et al. · Europe PMC (PubMed Central) · 22
Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials.
2018 · Neil H Shear, Carle Paul, et al. · PubMed · 21
Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings
2021 · Andrew Blauvelt, Nianwen Shi, et al. · Journal of the American Academy of Dermatology · 19
Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
2021 · Andrew Blauvelt, Nianwen Shi, et al. · Dermatology and Therapy · 9
PDF
Higher rates of skin clearance and efficacy in challenging body areas are associated with better health‐related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis
2021 · Adelaide A. Hebert, Margaret A. Bobonich, et al. · Pediatric Dermatology · 7
PDF
Obtaining a probability sample of a pregnancy cohort of births: a review of the problem and a practical solution
2025 · Michael R Elliott, Jean M Kerver, et al. · American Journal of Epidemiology · 6
PDF
Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study.
2022 · Andrew Blauvelt, Nianwen Shi, et al. · PubMed · 4
Candida Infections in Clinical Trials of Ixekizumab (Taltz), an Interleukin-17A Monoclonal Antibody, in Patients With Psoriasis or Psoriatic Arthritis
2019 · Margaret Bobonich, Melodie S. Young, et al. · Journal of the Dermatology Nurses’ Association · 4
Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
2022 · Andrew Blauvelt, Nianwen Shi, et al. · PharmacoEconomics - Open · 2
PDF
Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings
2022 · Andrew Blauvelt, Nianwen Shi, et al. · Journal of Medical Economics · 2
26654 Ixekizumab demonstrates greater medication adherence, persistence, and longer monotherapy duration than secukinumab, adalimumab, ustekinumab, and etanercept up to 3 years in the treatment of psoriasis: Real-world results
2021 · Andrew Blauvelt, Baojin Zhu, et al. · Journal of the American Academy of Dermatology · 2
Optimizing the key information section of informed consent documents in biomedical research: A multi-phased study using large language models
2026 · Shahana Chumki, Caleb Smith, et al. · Journal of Clinical and Translational Science · 1
PDF
Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA
2023 · Andrew Blauvelt, Nianwen Shi, et al. · Clinical Drug Investigation · 1
PDF
26718 Comparison of long-term treatment patterns between ixekizumab and secukinumab users among biologic-experienced psoriasis patients
2021 · Andrew Blauvelt, Nianwen Shi, et al. · Journal of the American Academy of Dermatology · 1
Clinical Outcomes at 1 Year in Early Psoriasis Area and Severity Index Responders Compared with Non-Responders: Subgroup Analysis of UNCOVER-3 Trial
2021 · D. Rosmarin, S. Smith, et al. · Skin Health and Disease · 1
Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings
2022 · Blauvelt, Andrew, Shi, Nianwen, et al. · Figshare
26291 Rapid skin improvement with ixekizumab treatment for pediatric patients with psoriasis: Results from IXORA-peds
2021 · Elizabeth Swanson, Lawrence Eichenfield, et al. · Journal of the American Academy of Dermatology
PBI12 Healthcare Resource Utilization and Costs in Patients with Psoriasis Who Switched to Biologic or Phosphodiesterase 4 Inhibitor Therapies Due to Inadequate Response
2021 · J.R. Curtis, M. Grabner, et al. · Value in Health
PBI17 Comparison of Switching Patterns Among Patients with Psoriasis Using Ixekizumab or Secukinumab in Real-World Settings
2021 · A. Blauvelt, N. Shi, et al. · Value in Health
PDF
13876 Achieving a PASI 50 at 2 weeks was associated with better long-term clinical outcomes and low discontinuation: A subgroup analysis of a phase 3 trial of ixekizumab and etanercept in moderate to severe psoriasis
2020 · David Rosmarin, David Shrom, et al. · Journal of the American Academy of Dermatology
L’ixékizumab a démontré une efficacité élevée et durable ainsi qu’un profil de tolérance cohérent chez des patients atteints de psoriasis modéré à sévère : 5 ans de suivi dans l’étude UNCOVER 3
2020 · A. Blauvelt, T. Mabuchi, et al. · Annales de Dermatologie et de Vénéréologie
Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis
2017 · Andrew Blauvelt, Craig Leonardi, et al. · SKIN The Journal of Cutaneous Medicine
PDF
Works count: 23
Citation count: 176
H-index: 6
I10-index: 4
Year
Topic
Type